Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. The lengthy process adversely impacts clinical trial start-up time and trial costs.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). The company’s Phase 2 trial, TRAILBLAZER-ALZ, studied the efficacy and safety of donanemab in patients with early, symptomatic AD.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

NOVEMBER 1, 2020

The trial is expected to enroll 160 patients. MS is an autoimmune, inflammatory disease of the central nervous system. billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. billion in 2018, and it is expected to be up to US$48.9

Clinical Trials 40

Clinical Trials Trials FDA Treatment 40

Vial

APRIL 18, 2024

Yet, hereditary and age-related retinal diseases present challenges, often leading to progressive vision loss and potential blindness. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

Vial

MAY 20, 2024

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. Adaptive trials allow researchers to modify specific parameters (e.g.,

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

JULY 29, 2021

In the second, Lilly shared data showing that treatment with donanemab drives a rapid reduction of a biomarker reflecting Alzheimer’s disease pathology, plasma P-tau217, which was detected within 12 weeks. Visit LillyMemoryTrials.com for additional information on enrolling in Alzheimer’s disease trials.

Disease 52

Disease Treatment Pharmacokinetics Trials 52

The Pharma Data

FEBRUARY 21, 2022

The company is advancing around 50 projects in ongoing clinical trials across a range of potential therapeutic modalities and indications, with a focus on oncology, cardiovascular and women’s health. Strong pipeline with robust late-stage development program and broad potential across indications.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Therapies 40

Therapies Trials Treatment Disease 40

Broad Institute

JUNE 24, 2025

Based on a technology developed by Broad Institute core member David Liu’s laboratory, the treatment is the first in a series of new medicines being tested to treat rare diseases by repairing patients’ particular genetic misspellings. s to be produced at scale, making them the standard of care for life-threatening rare genetic diseases.

Treatment 133

Treatment Disease DNA Clinical Trials 133

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). Alzprotect is committed to the development of innovative therapeutic solutions in the field of neurodegenerative diseases.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

The Pharma Data

MAY 3, 2021

Chronic disease care and management. “ Lilly is committed to helping address systemic inequities in health, including for those with non-communicable diseases such as diabetes, that too often have devastating effects on the lives of historically marginalized people,” said David A. www.lilly.com ?and? www.lilly.com/news.?I-LLY.

Clinical Trials 40

Clinical Trials Disease Therapies Trials 40

PPD

APRIL 14, 2025

Last year, an American Heart Association presidential advisory for the first time formally identified the strong connections between cardiovascular disease (CVD), kidney disease, Type 2 diabetes and obesity as reason to define cardiovascular-kidney-metabolic (CKM) syndrome.

Clinical Trials 52

Clinical Trials Trials Clinical Development Disease 52

SugarCone Biotech

JULY 6, 2025

Reporting in Nature Reviews Drug Discovery, @AsherMullard noted that Merus must provide the FDA with confirmatory evidence of benefit in both NSCLC and pancreatic adenocarcinoma in order to achieve full approval and that analysts predict annual sales of around $180 million by 2030 per consensus forecast via Cortellis.

Drug Development 56

Drug Development Drugs Clinical Trials Therapies 56

DrugBank

AUGUST 9, 2024

Moreover, the probability of success for a drug candidate entering clinical trials is only around 10%, highlighting the substantial risks involved. Humira , AbbVie's monoclonal antibody for autoimmune diseases, generated over $20 billion in annual revenue at its peak before losing patent exclusivity in 2023.  billion by 2030.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

The Pharma Data

JUNE 11, 2025

This expanded indication now includes the treatment of acute HCV—a condition that, if left untreated, can escalate to chronic liver disease, cirrhosis, or hepatocellular carcinoma. Early detection and rapid initiation of antiviral therapy are crucial to breaking the chain of transmission and preventing disease progression.

FDA Approval 40

FDA Approval FDA Virus Therapies 40

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. AstraZeneca is an established leader in respiratory care with a 50-year heritage.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

APRIL 24, 2021

The COVID-19 pandemic highlights the importance of robust health systems to respond to disease outbreaks and to control other deadly diseases such as malaria. In 2020, we discovered another novel malaria therapy, INE963, which has an entirely new mechanism of action and is expected to begin clinical trials in 2021.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

FEBRUARY 24, 2022

– Heart failure represents a significant, growing disease burden in the U.S., with more than 8 million cases expected by 2030. In the trial, Jardiance demonstrated a 21% relative risk reduction (3.3% In the trial, Jardiance demonstrated a 21% relative risk reduction (3.3% absolute risk reduction, 0.79

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

NOVEMBER 5, 2020

REGN-COV2 trial in the COVID-19 outpatient setting met primary and key secondary endpoints. This quarter we had robust top- and bottom-line growth driven by EYLEA in retinal diseases and Dupixent in atopic dermatitis and asthma. In September 2020 , the Company also reported the first data from a descriptive analysis in this trial.

Production 40

Production FDA Trials FDA Approval 40

The Pharma Data

MARCH 11, 2021

In the pharmaceutical sector, new technologies could help us not only to treat but probably cure or even prevent diseases,” Baumann said. Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

DECEMBER 18, 2020

billion: Norway has signed a new commitment of NOK 1 billion to the International Finance Facility for Immunisation (IFFIm), to be paid from 2021 to 2030. 9 of these candidates are still in development, and 7 are in clinical trials. This funding will support the Gavi COVAX AMC and comes on top of earlier commitments of NOK 164.1

Vaccine 52

Vaccine Government International Virus 52

PerkinElmer

JANUARY 25, 2023

Confronting and containing the spread of other infectious diseases like tuberculosis, influenza A and B as well as respiratory syncytial virus (RSV) also remained top global health priorities, as was testing to prevent the transmission of sexually transmitted infections, tickborne diseases and more.

Science 52

Science Laboratories Immune Response Disease 52

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. by the time Bancel made it over to Flagship, where Afeyan delivered his pitch: He wanted Bancel to work on a startup that had so far hired only a single staff scientist and conducted just one mouse trial. “It was about 6 p.m.

Engineering 87

Engineering Vaccine Production RNA 87

The Pharma Data

JUNE 13, 2025

2026–2030). Importantly, this will enable them to produce mRNA vaccines during periods between health crises, retaining trained personnel, technical expertise, and production capacity while retaining the ability to respond quickly in the event of future disease outbreaks.

Vaccine 40

Vaccine Production Clinical Trials Science 40

The Pharma Data

APRIL 27, 2021

reflecting increased competition partially offset by demand growth partly related to clinical trial supply and price upside in Europe. Rare Disease. Others Rare Disease. Total Rare Disease. In the first quarter, Rare Disease sales increased 4.4% Aubagio ® sales decreased 1.1% Net sales (€ million). Change at CER.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

FEBRUARY 8, 2021

We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks. Rare Disease. Others Rare Disease. Total Rare Disease. In the fourth quarter, Rare Disease sales increased 3.0% In 2020, Rare Disease sales increased 5.7% Net sales (€ million).

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

FEBRUARY 4, 2021

We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks. Rare Disease. Others Rare Disease. Total Rare Disease. In the fourth quarter, Rare Disease sales increased 3.0% In 2020, Rare Disease sales increased 5.7% Net sales (€ million).

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  This decline in R&D is attributed to scientific challenges associated with identifying new antibiotic targets and the relatively low return on investment compared to other therapeutic areas like oncology or rare diseases.  million deaths associated with it.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Government DNA 98

The Pharma Data

MAY 4, 2021

Lilly will donate both baricitinib (4 mg tablet) as well as bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together – providing options to treat COVID-19 patients at different stages of the disease. ” The allocation of therapies will be based on the disease burden and hospitalization rates in each country. .”

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

SEPTEMBER 15, 2020

More sensitive than traditional Pap cytology, this test allows clinicians to determine which HPV-positive women require further diagnostic procedures to prevent disease progression. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

Codon

NOVEMBER 3, 2024

Physicians working in the early 20th century had little choice but to treat the world’s most rampant infectious disease with methods such as these. But even now, more than a century later, TB remains the deadliest infectious disease on Earth, killing about 1.2 million people every year. Subscribe to Asimov Press.

Vaccine 114

Vaccine Trials Therapies Treatment 114

PPD

JANUARY 21, 2025

This decrease brings into sharp focus the growing challenges facing the field: Clinical trials now demand greater complexity, as well as increased data and diversity requirements. Trend 1: Scenario modeling will allow companies to evaluate entire trial timelines, revealing potential bottlenecks that help them achieve optimal outcomes.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52

Codon

MARCH 3, 2024

But why has it historically been difficult to do this, and how can animal trials open up approvals for similar drugs for humans in the near future? Related: Human trials of artificial wombs could start soon. per kilo by 2030. Link ANewInSituCryo-ElectronMicroscopyApproachtoDirectly Visualize Mutations in Mitochondrial Disease.

DNA 104

DNA Engineering Vaccine Virus 104

Codon

MAY 19, 2025

Since 2001, we’ve come a long way toward faster, more effective airborne disease detection. When an infectious disease goes unchecked, each case multiplies exponentially. Currently, we have two primary options for detecting infectious diseases: rapid antigen tests and laboratory-based molecular methods. Queen Mary 2.

Virus 75

Virus RNA Laboratories Hospitals 75